Search

Displaying results 3071 - 3080 of 10000 in total
  1. Drug

    Nilutamide

    go.drugbank.com/drugs/DB00665
    ApprovedInvestigational

    Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer.

  2. Drug

    Zalcitabine

    go.drugbank.com/drugs/DB00943
    ApprovedWithdrawn

    A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. … Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.

  3. Drug

    Acepromazine

    go.drugbank.com/drugs/DB01614
    InvestigationalVet approved

    Acepromazine is one of the phenothiazine derivative psychotropic drugs, used little in humans, however frequently in animals as a sedative and antiemetic.

  4. Drug

    Betamethasone phosphate

    go.drugbank.com/drugs/DB14669
    ApprovedVet approved

    [L11994] Betamethasone sodium phosphate was granted FDA approval on 3 March 1965.[L11994]

  5. Target

    Proteasome subunit alpha type-6

    go.drugbank.com/bio_entities/BE0003915
    TargetHumans

    Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. … This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex)

    Synonyms: Multicatalytic endopeptidase complex iota chain
  6. Drug

    Prezatide

    go.drugbank.com/drugs/DB11296
    Approved

    Prezatide is a tripeptide consisting of glycine, histidine, and lysine which readily forms a complex with copper ions [A19503]. Prezatide is used in cosmetic products for the skin and hair. … It is known to aid wound healing and its potential applications in chronic obstructive pulmonary disease and metastatic colon cancer are currently being investigated.

  7. Drug

    Odronextamab

    go.drugbank.com/drugs/DB16684
    ApprovedInvestigational

    [A254192] Odronextamab received its first approval in the European Union on August 26, 2024, for the treatment of relapsed or refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma … The partial clinical hold was later lifted in May 2021.

  8. Drug

    Umbralisib

    go.drugbank.com/drugs/DB14989
    ApprovedInvestigationalWithdrawn

    Marginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with [rituximab] (an anti-CD20 drug), either alone or in combination with chemotherapy. … [A229668] On February 5, 2021, the Food and Drug Administration granted accelerated approval to umbralisib, a kinase inhibitor for PI3K-delta and casein kinase CK1-epsilon, based on promising results

  9. Drug

    Andexanet alfa

    go.drugbank.com/drugs/DB14562
    Approved

    Andexanet alfa is currently under regulatory review by the European Union and is undergoing clinical development in Japan [A35518]. … It also prevents andexanet alfa from taking up space on phospholipid surface membranes, so that native FXa may bind and assemble the prothrominase complex [A35558].

  10. Drug

    Vonicog alfa

    go.drugbank.com/drugs/DB12872
    ApprovedInvestigational

    [A264389] Vonicog alfa works to reduce bleeding events and bleeding times in patients with vWD, who have deficiencies in VWF.[A264389] … [A264444] Used to treat von Willebrand Disease (vWD), it mimics the biological actions of endogenous VWF,[L51274] which is a critical plasma glycoprotein involved in platelet adhesion and aggregation.